+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Filgotinib Tablets Market - Global Forecast 2026-2032- Product Image
Filgotinib Tablets Market - Global Forecast 2026-2032- Product Image
Sale

Filgotinib Tablets Market - Global Forecast 2026-2032

  • Report

  • 185 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6116817
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Filgotinib Tablets Market is projected to reach USD 2.27 Billion in 2026. It is expected to continue growing at a CAGR of 14.39%, reaching USD 5.24 Billion by 2032.

Filgotinib Tablets: Executive Overview

Filgotinib tablets are an oral, selective Janus kinase 1 (JAK1) inhibitor developed for inflammatory diseases, particularly rheumatoid arthritis and ulcerative colitis. Clinical and regulatory relevance is shaped by demonstrated efficacy, safety characterization, treatment-line positioning, and jurisdiction-specific authorization decisions. Assessment should distinguish trial evidence from approved indications and account for the evolving safety framework applied to JAK inhibitors.

Regulatory and Treatment-Pathway Shifts Shaping Filgotinib

The landscape has shifted toward more selective use of advanced therapies, closer scrutiny of cardiovascular, thrombotic, malignancy, infection, and reproductive risks, and stronger requirements for post-marketing evidence. Filgotinib’s clinical role has also been influenced by differing regulatory outcomes across jurisdictions, payer controls, specialist prescribing, and the availability of alternative biologic and targeted synthetic disease-modifying therapies. These factors make local labeling and treatment guidelines central to interpretation.

Artificial Intelligence Strengthens Evidence and Safety Operations

Artificial intelligence can support filgotinib development and use by improving patient identification, trial recruitment, adverse-event signal detection, medical-record phenotyping, and analysis of treatment response. Its practical value depends on representative datasets, transparent validation, privacy safeguards, and clinician oversight. AI should augment-not replace-regulatory review and physician judgment, particularly where safety signals are rare, delayed, or confounded by disease severity and concomitant treatment.

Regional Insights Across Six Healthcare Environments

North America is characterized by stringent benefit-risk review, structured reimbursement management, and strong pharmacovigilance expectations. Europe places substantial emphasis on centralized and national regulatory processes, comparative clinical value, and health-technology assessment. Asia-Pacific combines advanced markets with varied regulatory capacity and access pathways. Latin America often requires navigation of heterogeneous registration, procurement, and private-insurance systems. Middle Eastern adoption is shaped by centralized purchasing, specialist centers, and national formularies, while Africa reflects uneven diagnostic capacity, affordability constraints, supply-chain limitations, and growing interest in locally relevant evidence.

Group-Level Dynamics Across ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN markets differ considerably in regulatory maturity, reimbursement, and specialist access, making country-level sequencing important. BRICS members combine large and diverse patient populations with varied public procurement and domestic-manufacturing policies. The European Union benefits from shared scientific and regulatory structures but retains national differences in pricing and reimbursement. G7 countries generally apply rigorous evidence and safety standards, while GCC systems often rely on centralized purchasing and specialist-led care. NATO membership is not a health-policy framework, but its members’ healthcare systems may share resilience priorities involving medicine supply continuity and emergency preparedness.

Country Perspectives: Evidence, Access, and Regulatory Context

Australia and Canada emphasize national regulatory review and public reimbursement assessment. Brazil and Mexico operate through mixed public-private systems with differing procurement and specialist access. China is expanding innovative-medicine capabilities while maintaining distinct regulatory and reimbursement processes. India combines a large generic-medicine ecosystem with uneven access to specialist rheumatology and gastroenterology services. Japan and South Korea apply detailed local evidence and pricing requirements. France, Germany, Italy, Spain, and the United Kingdom evaluate advanced therapies through national or regional health-technology and reimbursement structures. Russia’s access environment is shaped by domestic policy, procurement conditions, and international supply constraints. In the United States, prescribing, payer authorization, and post-market safety communication remain central considerations.

Actions for Leaders Managing Filgotinib Strategy

Industry leaders should maintain jurisdiction-specific evidence plans aligned with approved labeling, treatment guidelines, and evolving JAK-inhibitor safety requirements. Priorities include robust long-term pharmacovigilance, transparent communication of benefit-risk information, evidence generation in underrepresented populations, and health-economic analyses suited to each reimbursement setting. Organizations should also strengthen supply resilience, physician education, patient-support safeguards, and responsible AI governance. Decisions should be based on verified clinical and regulatory evidence rather than assumptions about adoption.

Research Methodology for a Verified Executive Assessment

This assessment uses a structured review of authoritative regulatory documents, approved product information, peer-reviewed clinical studies, trial registries, treatment guidelines, pharmacovigilance communications, and publicly available health-technology assessment materials. Evidence is interpreted by geography and stakeholder group, with explicit separation of established findings, jurisdiction-specific decisions, and areas requiring further validation. No market estimates, market sizing, market shares, forecasts, or company-specific comparisons are used.

Conclusion: Evidence Discipline Defines Filgotinib’s Role

Filgotinib tablets sit within a highly scrutinized field of targeted oral immunomodulators. Their clinical relevance depends on the balance among efficacy, safety, regulatory status, treatment sequencing, reimbursement, and practical access in each jurisdiction. Leaders can improve decision quality by integrating current labeling, independent clinical evidence, local policy, real-world safety monitoring, and carefully governed analytics into a continuously updated strategy.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Filgotinib Tablets Market, by Indication
7.1. Introduction
7.2. Rheumatoid Arthritis
7.2.1. BDMARDs Inadequate Responders
7.2.2. CsDMARDs Inadequate Responders
7.3. Ulcerative Colitis
7.3.1. Steroid-Dependent Patients
7.3.2. Steroid-Refractory Patients
8. Filgotinib Tablets Market, by Dosage Strength
8.1. Introduction
8.2. 100 Mg Tablet
8.3. 50 Mg Tablet
9. Filgotinib Tablets Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacies
9.2.1. Government Hospitals
9.2.2. Private Hospitals
9.3. Online Pharmacies
9.3.1. Direct To Patient Platforms
9.3.2. Third Party E Retailers
9.4. Retail Pharmacies
9.4.1. Chain Pharmacies
9.4.2. Independent Pharmacies
10. Filgotinib Tablets Market, by End User
10.1. Introduction
10.2. Home Healthcare
10.2.1. Home Health Nurse Administration
10.2.2. Self Administration
10.3. Hospitals
10.4. Specialty Clinics
10.4.1. Gastroenterology Clinics
10.4.2. Rheumatology Clinics
11. Filgotinib Tablets Market, by Treatment Line
11.1. Introduction
11.2. First Line Treatment
11.3. Second Line Treatment
11.3.1. BDMARDs Experienced
11.3.2. CsDMARDs Experienced
12. Filgotinib Tablets Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. Filgotinib Tablets Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. Filgotinib Tablets Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. Apino Pharma Co., Ltd.
16.2. Aurobindo Pharma Ltd.
16.3. Beijing Sjar Technology Development Co., Ltd.
16.4. Biocon Limited
16.5. Cadila Healthcare Limited
16.6. Cambrex Corporation
16.7. Cipla Limited
16.8. Divi's Laboratories Limited
16.9. Dr. Reddy's Laboratories Ltd.
16.10. Galapagos NV
16.11. Gilead Sciences, Inc.
16.12. Glenmark Pharmaceuticals Limited
16.13. Hetero Drugs Limited
16.14. Hutchison MediPharma International Limited
16.15. Lupin Limited
16.16. Metrochem API Private Limited
16.17. SETV Global Co., Ltd.
16.18. Shandong Perfect Biotechnology Co., Ltd.
16.19. Sun Pharmaceutical Industries Ltd.
16.20. Torrent Pharmaceuticals Limited
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global Filgotinib Tablets Market, Years Considered for the Study
FIGURE 2. Global Filgotinib Tablets Market, Research Design
FIGURE 3. Global Filgotinib Tablets Market, Research Framework
FIGURE 4. Global Filgotinib Tablets Market, Data Triangulation
FIGURE 5. Global Filgotinib Tablets Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Filgotinib Tablets Market Size, by Indication, 2025 vs 2032 (%)
FIGURE 7. Global Filgotinib Tablets Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Filgotinib Tablets Market Size, by Dosage Strength, 2025 vs 2032 (%)
FIGURE 9. Global Filgotinib Tablets Market Size, by Dosage Strength, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Filgotinib Tablets Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 11. Global Filgotinib Tablets Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Filgotinib Tablets Market Size, by End User, 2025 vs 2032 (%)
FIGURE 13. Global Filgotinib Tablets Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Filgotinib Tablets Market Size, by Treatment Line, 2025 vs 2032 (%)
FIGURE 15. Global Filgotinib Tablets Market Size, by Treatment Line, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Filgotinib Tablets Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global Filgotinib Tablets Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Filgotinib Tablets Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Filgotinib Tablets Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global Filgotinib Tablets Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Filgotinib Tablets Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Filgotinib Tablets Market Segmentation & Coverage
TABLE 2. Global Filgotinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 3. Global Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 4. Global Rheumatoid Arthritis Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Rheumatoid Arthritis Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Rheumatoid Arthritis Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global BDMARDs Inadequate Responders Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global BDMARDs Inadequate Responders Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global BDMARDs Inadequate Responders Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global CsDMARDs Inadequate Responders Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global CsDMARDs Inadequate Responders Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global CsDMARDs Inadequate Responders Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Ulcerative Colitis Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Ulcerative Colitis Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Ulcerative Colitis Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Steroid-Dependent Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Steroid-Dependent Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Steroid-Dependent Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Steroid-Refractory Patients Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Steroid-Refractory Patients Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Steroid-Refractory Patients Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 23. Global 100 Mg Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global 100 Mg Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global 100 Mg Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global 50 Mg Tablet Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global 50 Mg Tablet Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global 50 Mg Tablet Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 30. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Government Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Government Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Government Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Private Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Private Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Private Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 40. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 41. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 42. Global Direct To Patient Platforms Market Size, by Region, 2017-2032 (USD Million)
TABLE 43. Global Direct To Patient Platforms Market Size, by Group, 2017-2032 (USD Million)
TABLE 44. Global Direct To Patient Platforms Market Size, by Country, 2017-2032 (USD Million)
TABLE 45. Global Third Party E Retailers Market Size, by Region, 2017-2032 (USD Million)
TABLE 46. Global Third Party E Retailers Market Size, by Group, 2017-2032 (USD Million)
TABLE 47. Global Third Party E Retailers Market Size, by Country, 2017-2032 (USD Million)
TABLE 48. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 49. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 50. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 51. Global Chain Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 52. Global Chain Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 53. Global Chain Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 54. Global Independent Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 55. Global Independent Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 56. Global Independent Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 57. Global Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 58. Global Home Healthcare Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global Home Healthcare Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global Home Healthcare Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Home Health Nurse Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Home Health Nurse Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Home Health Nurse Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Self Administration Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Self Administration Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Self Administration Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Gastroenterology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Gastroenterology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Gastroenterology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Rheumatology Clinics Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Rheumatology Clinics Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Rheumatology Clinics Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 80. Global First Line Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global First Line Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global First Line Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Second Line Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Second Line Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Second Line Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global BDMARDs Experienced Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global BDMARDs Experienced Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global BDMARDs Experienced Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global CsDMARDs Experienced Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global CsDMARDs Experienced Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global CsDMARDs Experienced Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Filgotinib Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 93. Asia-Pacific Filgotinib Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Asia-Pacific Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 95. Asia-Pacific Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 96. Asia-Pacific Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 97. Asia-Pacific Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 98. Asia-Pacific Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 99. Asia-Pacific Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 101. Asia-Pacific Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 107. North America Filgotinib Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 108. North America Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 109. North America Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 110. North America Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 111. North America Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 112. North America Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. North America Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 114. North America Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 115. North America Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 116. North America Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 117. North America Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 118. North America Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 119. North America Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 120. North America Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 121. Latin America Filgotinib Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Latin America Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 123. Latin America Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 124. Latin America Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 125. Latin America Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 126. Latin America Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 127. Latin America Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 128. Latin America Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 129. Latin America Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 130. Latin America Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 131. Latin America Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 132. Latin America Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 133. Latin America Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 134. Latin America Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 135. Europe Filgotinib Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 136. Europe Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 137. Europe Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 138. Europe Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 139. Europe Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 140. Europe Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 141. Europe Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 142. Europe Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 143. Europe Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 144. Europe Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 145. Europe Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 146. Europe Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 147. Europe Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 148. Europe Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 149. Middle East Filgotinib Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 150. Middle East Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 151. Middle East Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 152. Middle East Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 153. Middle East Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 154. Middle East Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 155. Middle East Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 156. Middle East Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 157. Middle East Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 158. Middle East Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 159. Middle East Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 160. Middle East Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 161. Middle East Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 162. Middle East Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 163. Africa Filgotinib Tablets Market Size, by Region, 2017-2032 (USD Million)
TABLE 164. Africa Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 165. Africa Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 166. Africa Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 167. Africa Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 168. Africa Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 169. Africa Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 170. Africa Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 171. Africa Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 172. Africa Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 173. Africa Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 174. Africa Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 175. Africa Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 176. Africa Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 177. Global Filgotinib Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 178. ASEAN Filgotinib Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 179. ASEAN Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 180. ASEAN Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 181. ASEAN Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 182. ASEAN Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 183. ASEAN Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. ASEAN Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 185. ASEAN Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 186. ASEAN Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 187. ASEAN Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 188. ASEAN Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 189. ASEAN Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 190. ASEAN Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 191. ASEAN Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 192. GCC Filgotinib Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 193. GCC Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 194. GCC Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 195. GCC Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 196. GCC Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 197. GCC Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 198. GCC Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 199. GCC Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 200. GCC Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 201. GCC Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 202. GCC Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 203. GCC Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 204. GCC Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 205. GCC Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 206. European Union Filgotinib Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 207. European Union Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 208. European Union Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 209. European Union Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 210. European Union Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 211. European Union Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 212. European Union Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 213. European Union Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 214. European Union Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 215. European Union Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 216. European Union Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 217. European Union Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 218. European Union Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 219. European Union Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 220. BRICS Filgotinib Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 221. BRICS Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 222. BRICS Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 223. BRICS Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 224. BRICS Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 225. BRICS Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 226. BRICS Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 227. BRICS Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 228. BRICS Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 229. BRICS Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 230. BRICS Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 231. BRICS Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 232. BRICS Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 233. BRICS Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 234. G7 Filgotinib Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 235. G7 Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 236. G7 Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 237. G7 Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 238. G7 Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 239. G7 Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 240. G7 Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 241. G7 Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 242. G7 Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 243. G7 Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 244. G7 Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 245. G7 Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 246. G7 Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 247. G7 Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 248. NATO Filgotinib Tablets Market Size, by Group, 2017-2032 (USD Million)
TABLE 249. NATO Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 250. NATO Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 251. NATO Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 252. NATO Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 253. NATO Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 254. NATO Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 255. NATO Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 256. NATO Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 257. NATO Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 258. NATO Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 259. NATO Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 260. NATO Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 261. NATO Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 262. Global Filgotinib Tablets Market Size, by Country, 2017-2032 (USD Million)
TABLE 263. United States Filgotinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 264. United States Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 265. United States Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 266. United States Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 267. United States Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 268. United States Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 269. United States Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 270. United States Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 271. United States Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 272. United States Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 273. United States Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 274. United States Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 275. United States Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 276. United States Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 277. Canada Filgotinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 278. Canada Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 279. Canada Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 280. Canada Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 281. Canada Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 282. Canada Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 283. Canada Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 284. Canada Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 285. Canada Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 286. Canada Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 287. Canada Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 288. Canada Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 289. Canada Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 290. Canada Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 291. Mexico Filgotinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 292. Mexico Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 293. Mexico Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 294. Mexico Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 295. Mexico Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 296. Mexico Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 297. Mexico Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 298. Mexico Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 299. Mexico Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 300. Mexico Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 301. Mexico Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 302. Mexico Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 303. Mexico Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 304. Mexico Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 305. Brazil Filgotinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 306. Brazil Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 307. Brazil Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 308. Brazil Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 309. Brazil Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 310. Brazil Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 311. Brazil Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 312. Brazil Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 313. Brazil Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 314. Brazil Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 315. Brazil Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 316. Brazil Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 317. Brazil Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 318. Brazil Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 319. United Kingdom Filgotinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 320. United Kingdom Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 321. United Kingdom Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 322. United Kingdom Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 323. United Kingdom Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 324. United Kingdom Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 325. United Kingdom Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 326. United Kingdom Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 327. United Kingdom Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 328. United Kingdom Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 329. United Kingdom Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 330. United Kingdom Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 331. United Kingdom Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 332. United Kingdom Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 333. Germany Filgotinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 334. Germany Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 335. Germany Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 336. Germany Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 337. Germany Filgotinib Tablets Market Size, by Dosage Strength, 2017-2032 (USD Million)
TABLE 338. Germany Filgotinib Tablets Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 339. Germany Filgotinib Tablets Market Size, by Hospital Pharmacies, 2017-2032 (USD Million)
TABLE 340. Germany Filgotinib Tablets Market Size, by Online Pharmacies, 2017-2032 (USD Million)
TABLE 341. Germany Filgotinib Tablets Market Size, by Retail Pharmacies, 2017-2032 (USD Million)
TABLE 342. Germany Filgotinib Tablets Market Size, by End User, 2017-2032 (USD Million)
TABLE 343. Germany Filgotinib Tablets Market Size, by Home Healthcare, 2017-2032 (USD Million)
TABLE 344. Germany Filgotinib Tablets Market Size, by Specialty Clinics, 2017-2032 (USD Million)
TABLE 345. Germany Filgotinib Tablets Market Size, by Treatment Line, 2017-2032 (USD Million)
TABLE 346. Germany Filgotinib Tablets Market Size, by Second Line Treatment, 2017-2032 (USD Million)
TABLE 347. France Filgotinib Tablets Market Size, 2017-2032 (USD Million)
TABLE 348. France Filgotinib Tablets Market Size, by Indication, 2017-2032 (USD Million)
TABLE 349. France Filgotinib Tablets Market Size, by Rheumatoid Arthritis, 2017-2032 (USD Million)
TABLE 350. France Filgotinib Tablets Market Size, by Ulcerative Colitis, 2017-2032 (USD Million)
TABLE 351. France Filgotinib Tablets Market Si

Companies Mentioned

  • Apino Pharma Co., Ltd.
  • Aurobindo Pharma Ltd.
  • Beijing Sjar Technology Development Co., Ltd.
  • Biocon Limited
  • Cadila Healthcare Limited
  • Cambrex Corporation
  • Cipla Limited
  • Divi's Laboratories Limited
  • Dr. Reddy's Laboratories Ltd.
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Glenmark Pharmaceuticals Limited
  • Hetero Drugs Limited
  • Hutchison MediPharma International Limited
  • Lupin Limited
  • Metrochem API Private Limited
  • SETV Global Co., Ltd.
  • Shandong Perfect Biotechnology Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Limited

Related Topics

Related Reports

JAK Inhibitors - Competitive Landscape, 2026 - Product Image

JAK Inhibitors - Competitive Landscape, 2026

  • Report
  • 180 Pages
  • Global
From
Oral JAK Inhibitors Market - Global Forecast 2026-2032 - Product Image

Oral JAK Inhibitors Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Rheumatoid Arthritis Drugs Market: Strategic Landscape, Pipeline Innovations, and Economic Trajectories - Product Image

Rheumatoid Arthritis Drugs Market: Strategic Landscape, Pipeline Innovations, and Economic Trajectories

  • Report
  • 91 Pages
  • Global
From
Juvenile Idiopathic Arthritis (JIA) - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Juvenile Idiopathic Arthritis (JIA) - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 225 Pages
  • Global
From
Axial Spondyloarthritis Market - Global Forecast 2026-2032 - Product Image

Axial Spondyloarthritis Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.